Decadron (Dexamethasone) Shortage: What Providers and Prescribers Need to Know in 2026

Dexamethasone — the generic form of the discontinued brand Decadron — is one of the most widely prescribed corticosteroids in clinical medicine. Used in settings ranging from oncology and neurosurgery to primary care and emergency medicine, it is an indispensable therapeutic agent. However, its injectable formulation has been subject to ongoing supply disruptions for over a decade, and providers in 2026 should maintain protocols for managing prescribing when availability is constrained.

Formulation Availability Summary for Clinicians (2026)

• Oral tablets (0.5–20 mg): Generally widely available with no active shortage. Multiple generic manufacturers supply the market. Standard first-line option for outpatient prescribing.
• Oral concentrate (1 mg/mL): Generally available; fewer pharmacies stock it routinely. May require ordering. Useful for patients with dysphagia.
• Injectable (4 mg/mL, 10 mg/mL): Ongoing intermittent shortage. Has been on FDA Drug Shortage Database for 10+ years. Availability varies by vial size, concentration, and distributor relationship. Preservative-free formulations most affected.
• Brand-name Decadron: Discontinued in the U.S. Prescriptions written for 'Decadron' will be filled with generic dexamethasone. Consider updating prescription templates accordingly.

Clinical Context: Why Dexamethasone Injection Remains in Shortage

The injectable shortage is driven by structural pharmaceutical supply chain factors: a limited manufacturing base for sterile injectables, thin margins on generic products reducing competitive entry, and vulnerability to single-source disruptions. The COVID-19 pandemic amplified these issues significantly — dexamethasone became a standard of care for severe COVID-19 (6 mg IV/oral daily for 10 days in patients requiring supplemental oxygen), creating demand pressure that exceeded existing production capacity.

As of early 2026, the total number of drug shortages in the U.S. has declined from 323 at the start of 2024 to approximately 195 as of February 2026. However, dexamethasone injection remains among those with persistent, decade-long listing status.

Glucocorticoid Dose Equivalency Table

When substituting for dexamethasone, the following dose equivalencies serve as a starting point. Individual patient response, indication, and comorbidities should guide final dosing decisions:

• Dexamethasone 0.75 mg ≈ Methylprednisolone 4 mg ≈ Prednisone 5 mg ≈ Prednisolone 5 mg ≈ Hydrocortisone 20 mg
• Dexamethasone 4 mg ≈ Methylprednisolone 21 mg ≈ Prednisone 27 mg ≈ Prednisolone 27 mg
• Dexamethasone 6 mg (COVID dose) ≈ Methylprednisolone 40 mg ≈ Prednisone 40 mg (though oral route was also shown effective for COVID)

Note: Dexamethasone has minimal mineralocorticoid activity. When switching to methylprednisolone (moderate mineralocorticoid) or hydrocortisone (significant mineralocorticoid activity), monitor for fluid retention and electrolyte changes.

Indication-Specific Prescribing Considerations During Shortage

Cerebral edema: Dexamethasone remains the standard of care for peritumoral and vasogenic cerebral edema — it has been used for this indication for over 60 years and no other agent has demonstrated superior efficacy. If injectable is unavailable, oral dexamethasone can be considered for maintenance in stable patients. Avoid switching to agents with significant mineralocorticoid activity.

Chemotherapy-induced nausea/vomiting (CINV): Oral dexamethasone is typically interchangeable with IV for most CINV regimens when patients can take oral medications. If switching to IV methylprednisolone, dose conversion and institutional protocol review is necessary.

Croup (pediatric): Oral or nebulized dexamethasone (0.6 mg/kg, max 16 mg) is the standard of care. Oral and IM routes are both effective — oral preferred when injectable is constrained. Prednisolone (1 mg/kg/day) is an acceptable alternative.

Multiple myeloma (Hemady regimens): High-dose dexamethasone (40 mg weekly or 40 mg days 1-4/9-12/17-20) is protocol-specific. Consult treating hematologist/oncologist before any substitution.

General anti-inflammatory/allergic reactions: Prednisone or methylprednisolone are readily available alternatives with equivalent efficacy for most outpatient indications. Standard dose conversion applies.

Prescribing Practice Recommendations

1. Update prescription templates to read 'dexamethasone' (generic) rather than 'Decadron' to prevent pharmacy confusion.
2. For ongoing patients, consider prescribing individual tablets rather than taper packs — individual tablets are more consistently available and often less expensive.
3. Pre-authorize alternatives in patient charts, particularly for those on chronic corticosteroid therapy, so patients don't face treatment gaps when calling for a substitution.
4. Direct patients to medfinder for Providers — a tool that checks real-time dexamethasone availability at pharmacies in your patients' area, reducing calls to your office and preventing failed fills.
5. Monitor the FDA Drug Shortage Database (accessdata.fda.gov/scripts/drugshortages/) for real-time shortage status updates, particularly for injectable formulations.

Insurance Considerations When Switching Agents

Most corticosteroid alternatives (prednisone, prednisolone, methylprednisolone) are Tier 1 preferred generics on formularies and require no prior authorization. However, for patients switching from a protocol-specific dexamethasone regimen (e.g., multiple myeloma), prior authorization requirements may apply to alternative agents. Many plans have shortage override protocols — referencing the FDA Drug Shortage Database listing in your PA request strengthens approval. See our guide on helping patients find Decadron in stock for additional patient-facing strategies.